» Authors » Martin J Scurr

Martin J Scurr

Explore the profile of Martin J Scurr including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 471
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Scurr M, Lippiatt G, Capitani L, Bentley K, Lauder S, Smart K, et al.
Nat Commun . 2022 Sep; 13(1):5422. PMID: 36130936
T cells specific for SARS-CoV-2 are thought to protect against infection and development of COVID-19, but direct evidence for this is lacking. Here, we associated whole-blood-based measurement of SARS-CoV-2-specific interferon-γ-positive...
2.
Tallantyre E, Scurr M, Vickaryous N, Richards A, Anderson V, Baker D, et al.
Mult Scler Relat Disord . 2022 Jun; 64:103937. PMID: 35700625
Background: People with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine...
3.
Scurr M, Zelek W, Lippiatt G, Somerville M, Burnell S, Capitani L, et al.
Immunology . 2021 Nov; 165(2):250-259. PMID: 34775604
Accurate assessment of SARS-CoV-2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T-cell responses are...
4.
Bradley R, Ponsford M, Scurr M, Godkin A, Jolles S
J Clin Immunol . 2021 Oct; 42(1):32-35. PMID: 34714497
No abstract available.
5.
Tallantyre E, Vickaryous N, Anderson V, Asardag A, Baker D, Bestwick J, et al.
Ann Neurol . 2021 Oct; 91(1):89-100. PMID: 34687063
Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple...
6.
Thomson A, Bento D, Scurr M, Smart K, Somerville M, Keita A, et al.
Br J Cancer . 2021 Mar; 124(9):1552-1555. PMID: 33674735
Background: The T cell cytokine profile is a key prognostic indicator of post-surgical outcome for colorectal cancer (CRC). Whilst T1 (IFN-γ) cell-mediated responses generated in CRC are well documented and...
7.
Scurr M, Greenshields-Watson A, Campbell E, Somerville M, Chen Y, Hulin-Curtis S, et al.
Clin Cancer Res . 2020 Mar; 26(13):3360-3370. PMID: 32122920
Purpose: Broadly expressed, highly differentiated tumor-associated antigens (TAA) can elicit antitumor immunity. However, vaccines targeting TAAs have demonstrated disappointing clinical results, reflecting poor antigen selection and/or immunosuppressive mechanisms. Experimental Design:...
8.
Thomson A, Smart K, Somerville M, Lauder S, Appanna G, Horwood J, et al.
BMC Gastroenterol . 2019 Jun; 19(1):98. PMID: 31221083
Background: The relationship between intestinal epithelial integrity and the development of intestinal disease is of increasing interest. A reduction in mucosal integrity has been associated with ulcerative colitis, Crohn's disease...
9.
Besneux M, Greenshields-Watson A, Scurr M, MacLachlan B, Christian A, Davies M, et al.
Cancer Immunol Immunother . 2018 Nov; 68(2):247-256. PMID: 30406375
The oncofoetal antigen 5T4 is a promising T cell target in the context of colorectal cancer, as demonstrated by a recent clinical study where 5T4-specific T cell responses, induced by...
10.
Clement M, Marsden M, Stacey M, Abdul-Karim J, Gimeno Brias S, Costa Bento D, et al.
PLoS Pathog . 2016 Dec; 12(12):e1006050. PMID: 27926930
CD4+ T cells support host defence against herpesviruses and other viral pathogens. We identified that CD4+ T cells from systemic and mucosal tissues of hosts infected with the β-herpesviridae human...